title: Why wasn't an investigational new drug (IND) application required before appropriate study?
authors.affiliation: The Deem Corporation, P.O. Box 44069, Omaha, NE 68144, USA.
authors.forename: Dennis M
authors.initials: DM
authors.lastname: Maloney
mesh_terms: D001249:Asthma; D015142:Baltimore; D018849:Controlled Clinical Trials as Topic / Q000009:adverse effects / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational / Q000009:adverse effects*; D028744:Ethics Committees, Research; D005260:Female; D019983:Guideline Adherence; D018738:Hexamethonium / Q000009:adverse effects*; D006785:Hospitals, University; D006801:Humans; D017387:Investigational New Drug Application / Q000331:legislation & jurisprudence; D033281:Nontherapeutic Human Experimentation / Q000331:legislation & jurisprudence*; D035842:Research Subjects; D014481:United States; D014486:United States Food and Drug Administration; D018172:United States Office of Research Integrity
chemical_list: D015507:Drugs, Investigational; D018738:Hexamethonium